Skip to content

Case Series With Saneso 360° Gastroscope

Case Series With Saneso 3600 Gastroscope

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04621591
Enrollment
22
Registered
2020-11-09
Start date
2020-08-01
Completion date
2020-09-09
Last updated
2020-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGD Procedure

Brief summary

To confirm the procedural performance of the Saneso 360° gastroscope in Esophago-gastro-duodenoscopy (EGD) procedures.

Detailed description

This study is a prospective, multicenter case series per standard of care EGD procedures using a nonsignificant risk Saneso 360° gastroscope. 20 cases will be included at up to five (5) clinical sites. Patients who meet all eligibility criteria will be included and will have a clinically indicated EGD procedure performed using the study device. Immediately thereafter, patients will have an EGD procedure using a standard Gastroscope (Olympus GIF180) by a second endoscopist. Enrolled subjects will be followed for 7 days after their procedure. If the procedure is not successful with the study device, the endoscopist will complete the procedure with a traditional gastroscope used at each facility.

Interventions

DEVICESaneso 360° gastroscope

Subjects will have a clinically indicated per standard of care routine EGD procedure performed with the Saneso 360° gastroscope.

Sponsors

West Virginia University
CollaboratorOTHER
Saneso Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 74 Years
Healthy volunteers
No

Inclusion criteria

* 18 -74 years of age * Willing and able to comply with the study procedures and provide written informed consent to participate in the study. * Scheduled for a clinically indicated routine EGD procedure * ASA class 1-3.

Exclusion criteria

* Altered esophageal, gastric, or duodenal anatomy * Pregnant women, children under 18 years of age, and adults over 75 years of age. * Subjects for whom routine endoscopic procedures are contraindicated due to comorbid medical conditions. * Patients who are currently enrolled in another investigational study that would directly interfere with the current study, without prior written approval from the sponsor * ASA class 4-5.

Design outcomes

Primary

MeasureTime frameDescription
Successful EGDWithin 24 hours on study dayProcedure success is assessed at the end of the procedure 1). Procedure success is defined as by successful intubation of the third portion of the duodenum. Photograph of the third portion of the duodenum will be taken.

Secondary

MeasureTime frameDescription
Endoscopist qualitative rating of the Saneso 360° gastroscopeWithin 24 hours on study dayEndoscopists will rate their experience with the Saneso 360° gastroscope immediately following the completion of the study procedure 1) using a five-point Likert scales (5 - excellent; 4 - good; 3- acceptable; 2- difficult; and 1-unacceptable).
Endoscopist qualitative rating of the Saneso 360° gastroscope compared to their past experience with traditional gastroscopes (TG)Within 7 days of completion of the studyEndoscopist qualitative rating of the Saneso 360° gastroscope compared to their past experience with traditional gastroscopes (TG) as it pertains to various design and performance related attributes using a 3-point Likert scale (Saneso gastroscope is 5 - superior to TG; 3 - the same as TG; 1 - inferior to TG).
Evaluation of adverse events (AEs) related to the device.Within 7 days of completion of the studyAEs are assessed through 7 days after the procedure.
Evaluation of any potential mucosal injuryImmediately after the use of the deviceEvaluation of any potential mucosal injury resulting from use of the study device immediately following the use of the device (0- no mucosal damage; 1- erythema; 2-bleeding; 3- superficial mucosal tear; 4- deep mucosal tear).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026